Millennium Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of medicines for cancer and inflammatory diseases. It markets VELCADE (bortezomib) for injection in the relapsed multiple myeloma and relapsed non-Hodgkin’s lymphoma settings. The company also conducts ongoing VELCADE clinical trials, such as three multi-center phase III clinical trials in front-line multiple myeloma patients; a randomized phase III clinical trial in patients with relapsed follicular or marginal zone lymphoma; and a randomized phase II clinical trial in patients with relapsed non-small cell lung cancer. In addition, it has various product candidates in clinical and late preclinical development, including MLN518 in phase I/phase II trials for acute myeloid leukemia; MLN8054 in phase I clinical trial for advanced malignancies; MLN8237 in preclinical trial for advanced malignancies; MLN0002 for the treatment of crohn’s disease and ulcerative colitis; and MLN1202 in phase IIa for Multiple sclerosis, as well as completed phase IIa trial for atherosclerosis. Its clinical or preclinical trial status drug candidates also include MLN3897 and MLN3701 for chronic inflammatory diseases, such as rheumatoid arthritis; MLN0415 in phase I trial for rheumatoid arthritis; and MLN6095 in preclinical stage for inflammatory diseases. Millennium Pharmaceuticals has collaboration agreements with Ortho Biotech Products, Inc. for the commercialization of VELCADE, and with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. for the clinical development of VELCADE; Schering Corporation, Schering-Plough, Ltd., and GlaxoSmithKline plc for marketing INTEGRILIN; and Sanofi-Aventis Group for the joint discovery, development, and commercialization of small molecule drugs for the treatment of inflammatory diseases. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.